EMA establishes regular procedure for scientific advice on certain high-risk medical devices
European Medicines Agency (EMA), in close collaboration with the European Commission, has established a standard procedure for manufacturers of certain high-risk medical devices to request scientific advice on their intended clinical development strategy and proposals for clinical investigation.
"Manufacturers of class III devices and class IIb active devices intended to administer or remove medicines can now submit their request for advice via a portal and consult the medical device expert panels at different stages of the clinical development," EMA stated.
Advice given by the medical device expert panels is a key tool to foster innovation and promote faster patient access to safer and more effective devices.
Read also: GSK Depemokimab accepted for review by EMA for use in asthma with type 2 inflammation, CRSwNP
This regular scientific advice procedure follows a pilot launched in February 2023, which has helped to establish this procedure and gathered positive feedback from manufacturers and panel experts. EMA will publish a report on the pilot in the coming weeks.
There are currently no fees associated with these requests.
Read also: Aurobindo Pharma arm gets positive opinion for biosimilar Dyrupeg from EMA
Manufacturers of high-risk medical devices intended for the treatment of a rare condition should apply for advice via the ongoing pilot programme to support orphan medical devices, EMA added.
EMA provides the secretariat to support the expert panels, based on Regulation (EU) 2022/123
Read also: Bayer seeks approval of finerenone in heart failure in EU
